Jaguar Health Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · June 30, · · December 31,
(In thousands, except share and per share data) · 2024 · 2023
· · (unaudited) · · ·
Assets · · · · ·
Current assets:
Cash	$16,049	$6,469
Accounts receivable, net	1,299	1,967
Other receivable	65	217
Inventory	9,556	9,189
Prepaid expenses and other current assets	13,142	10,121
Total current assets	40,111	27,963
Property and equipment, net	488	496
Operating lease - right-of-use asset	1,176	1,176
Intangible assets, net	19,408	20,116
Other assets	276	1,012
Total assets	$61,459	$50,763

Liabilities, Redeemable preferred stock, and Stockholders' equity
Current liabilities:
Accounts payable	$4,093	$4,974
Accrued liabilities	3,339	3,798
Deferred revenue	170	—
Operating lease liability, current	416	348
Notes payable, net of discount (includes note designated at Fair Value Option amounting to $10.5 million as of June 30, 2024, and $0 December 31, 2023, respectively)	11,115	4,867
Total current liabilities	19,133	13,987
Operating lease liability, net of current portion	812	886
Deferred revenue - long term	638	—
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $21.8 million as of June 30, 2024, and $31.0 million December 31, 2023, respectively)	21,813	30,993
Total liabilities	42,396	45,866

Commitments and contingencies (See Note 6)
Redeemable preferred stock: $0.0001 par value; 179 and 0 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December 31, 2023; 99 and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023	2,485	—

Stockholders' equity
Series G convertible preferred stock: $0.0001 par value; 137 and 137 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December 31, 2023; 0 and 122 shares issued and outstanding at June 30, 2024 and December 31, 2023	—	—
Series H convertible preferred stock: $0.0001 par value; 105 and 105 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December 31, 2023; zero shares issued and outstanding at June 30, 2024 and December 31, 2023	—	—
Series I convertible preferred stock: $0.0001 par value; 118 and 118 shares designated from 10,000,000 preferred stock authorized at June 30, 2024, and December 31, 2023; 0 and 56 shares issued and outstanding at June 30, 2024 and December 31, 2023	—	—
Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at June 30, 2024, and December 31, 2023; 7,827,609 and 1,223,553 issued and outstanding at June 30, 2024, and December 31, 2023	—	—
Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at June 30, 2024, and December 31, 2023; 9 shares issued and outstanding at June 30, 2024, and December 31, 2023	—	—
Additional paid-in capital	344,155	313,861
Non-controlling interest	(328)	(64)
Accumulated deficit	(326,707)	(308,248)
Accumulated other comprehensive loss	(542)	(652)
Total stockholders' equity	16,578	4,897
Total liabilities, redeemable preferred stock and stockholders' equity	$61,459	$50,763

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.